Compositions and methods for treating polymyalgia rheumatica by administering an IL-6R antagonist

IL-6 receptor antagonist therapy addresses the limitations of long-term glucocorticoid treatment for PMR by effectively managing symptoms and minimizing side effects, enabling steroid reduction or discontinuation.

JP2026143668APending Publication Date: 2026-09-08REGENERON PHARMACEUTICALS INC +1
0 Cites 0 Cited by

Patent Information

Application Number
JP2026096687
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-02-23
Filing Date
2026-06-10
Publication Date
2026-09-08

AI Technical Summary

Technical Problem

Current treatments for polymyalgia rheumatica (PMR), primarily long-term oral glucocorticoid therapy, are associated with potential comorbidities and have limited efficacy in some patients, necessitating the development of alternative therapies with fewer adverse side effects.

Method used

Administering an IL-6 receptor antagonist, such as an anti-IL-6R antibody, in combination with corticosteroids like prednisone, to treat PMR, allowing for a gradual reduction or discontinuation of steroid use, particularly in steroid-dependent or refractory cases.

Benefits of technology

The IL-6 receptor antagonist therapy effectively reduces PMR symptoms, decreases glucocorticoid toxicity, and achieves remission with fewer disease flares, improving patient-reported outcomes and reducing long-term steroid-related complications.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

To provide an effective treatment for polymyalgia rheumatica (PMR) with fewer harmful side effects. [Solution] An antibody or an antigen-binding fragment thereof that specifically binds to the IL-6 receptor is provided for use in a method for treating polymyalgia rheumatica (PMR) in subjects requiring treatment for PMR.
Need to check novelty before this filing date? Find Prior Art